FDA to Rethink Enforcement Discrection Policy Over LDTs at July Public Meeting

The FDA said this week that due to "public health concerns, the agency believes it is time to reconsider its policy of enforcement discretion over LDTs."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.